Wille

Amended Claims

- 1. An AAV vector having a nucleic acid coding for a fusion polypeptide, the fusion polypeptide comprising a structural papilloma virus (poly)peptide and a non-transforming (poly)peptide coded by an early papilloma virus gene.
- 2. The vector according to claim 1, characterized in that the papilloma virus is a HPV.
- 3. The vector according to claim 2, characterized in that the HPV is selected from the group consisting of HPV 16, 18, 33, 35 and 45.
- 4. The vector according to any one of claims 1 to 3, characterized in that the nucleic acid is under the control of a constitutive or inducible promoter.
- 5. The vector according to claim 4, characterized in that the promoter is a tissue specific or tumor-specific promoter.
- 6. The vector according to any one of claims 1 to 5, characterized in that the structural papilloma virus (poly)peptide is coded by L1-ORF and by part thereof, respectively.
- 7. The vector according to any one of claims 1 to 6, characterized in that the non-transforming (poly)peptide coded by an early papilloma virus gene is coded by E6-ORF or E7-ORF and by part thereof, respectively.
- 8. A vaccination agent containing the vector according to any one of claims 1 to 7 and conventional auxiliary agents.

- 9. The vaccination agent according to claim 8, characterized in that further substances activating the immune system are present.
- 10. The vaccination agent according to claim 8 or 9, characterized in that the vector is present in cells.
- 11. The vaccination agent according to claim 10, characterized in that the cells are tumor cells and/or pre-tumor cells, which are associated to papilloma viruses and sequences thereof, respectively.
- 12. The vaccination agent according to claim 11, characterized in that the tumor cells and the pre-tumor cells are inactivated.
- 13. Use of the vector according to any one of claims 1 to 7 and the vaccination agent according to any one of claims 8 to 12 for activating the immune system against cells associated to papilloma viruses and sequences thereof, respectively.